BILASIGN Tablet is an advanced, second-generation antihistamine designed to manage a range of allergic conditions with minimal central nervous system side effects. The active pharmaceutical ingredient in BILASIGN is Bilastine, a highly selective H1 histamine receptor antagonist that provides potent peripheral antihistaminic effects without crossing the blood-brain barrier. This selective action ensures effective relief from allergy symptoms such as sneezing, nasal congestion, rhinorrhea, itchy eyes, and urticaria, while maintaining patient alertness and performance throughout the day.

Bilastine is known for its rapid onset of action, with noticeable symptom improvement within one hour of oral administration. Its effects last for 24 hours, making it suitable for once-daily dosing, which enhances compliance and convenience for patients. This is especially valuable for individuals suffering from chronic or seasonal allergic conditions, where consistent and long-term symptom control is essential for quality of life and daily productivity.

BILASIGN Tablet is primarily indicated for the treatment of allergic rhinitis, both seasonal and perennial, and chronic spontaneous urticaria. Allergic rhinitis is a widespread condition caused by hypersensitivity to environmental allergens such as pollen, dust mites, pet dander, and mold spores. It is characterized by symptoms like nasal congestion, runny nose, itchy nose, and sneezing, often accompanied by ocular symptoms like redness and tearing. Chronic urticaria, on the other hand, is marked by the spontaneous appearance of hives, itching, and swelling that persists for weeks or months without an identifiable trigger. In both conditions, the release of histamine from mast cells plays a key role, and blocking this histamine action at the receptor site is central to effective management.